Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
0.3302
Dollar change
-0.0050
Percentage change
-1.49
%
Index- P/E- EPS (ttm)-2.16 Insider Own48.11% Shs Outstand8.65M Perf Week-16.64%
Market Cap2.86M Forward P/E- EPS next Y- Insider Trans-44.96% Shs Float4.49M Perf Month-33.96%
Income-16.91M PEG- EPS next Q- Inst Own4.03% Short Float6.11% Perf Quarter-49.74%
Sales0.00M P/S- EPS this Y- Inst Trans-0.93% Short Ratio0.92 Perf Half Y-44.03%
Book/sh0.35 P/B0.94 EPS next Y- ROA-96.91% Short Interest0.27M Perf Year-69.43%
Cash/sh0.09 P/C3.48 EPS next 5Y- ROE-188.43% 52W Range0.30 - 1.50 Perf YTD-43.10%
Dividend Est.- P/FCF- EPS past 5Y33.58% ROI-186.48% 52W High-77.99% Beta1.26
Dividend TTM- Quick Ratio0.81 Sales past 5Y1609.08% Gross Margin92.49% 52W Low10.07% ATR (14)0.07
Dividend Ex-Date- Current Ratio0.81 EPS Y/Y TTM-103.25% Oper. Margin0.00% RSI (14)37.89 Volatility9.26% 21.82%
Employees6 Debt/Eq2.20 Sales Y/Y TTM-100.00% Profit Margin- Recom3.00 Target Price2.00
Option/ShortNo / Yes LT Debt/Eq1.99 EPS Q/Q-104.64% Payout- Rel Volume0.40 Prev Close0.34
Sales Surprise- EPS Surprise- Sales Q/Q-100.00% EarningsMay 16 AMC Avg Volume299.22K Price0.33
SMA20-23.41% SMA50-33.15% SMA200-45.45% Trades Volume118,376 Change-1.49%
Date Action Analyst Rating Change Price Target Change
Dec-13-21Downgrade Chardan Capital Markets Buy → Neutral $2.25 → $0.40
Dec-18-20Initiated BMO Capital Markets Outperform $6
Nov-20-19Initiated Guggenheim Buy $9
Jun-06-24 09:52PM
04:01PM
May-29-24 07:39AM
May-23-24 04:01PM
May-16-24 09:52PM
04:08PM Loading…
04:08PM
Apr-22-24 04:01PM
Feb-06-24 07:05AM
Feb-05-24 04:01PM
Dec-08-23 08:40AM
Nov-28-23 04:01PM
Aug-23-23 09:48AM
Aug-11-23 04:01PM
Jul-14-23 04:01PM
May-26-23 04:01PM
04:01PM Loading…
May-19-23 04:01PM
May-04-23 04:01PM
Apr-27-23 07:00AM
Mar-27-23 04:01PM
Feb-24-23 05:10PM
Dec-14-22 05:00AM
Nov-14-22 04:01PM
Sep-26-22 04:01PM
Sep-01-22 07:00AM
Aug-15-22 04:01PM
Jul-20-22 04:01PM
Jun-29-22 12:00PM
May-27-22 04:01PM
May-17-22 07:00AM
May-16-22 04:01PM
07:21PM Loading…
May-10-22 07:21PM
May-09-22 07:00AM
Mar-25-22 04:15PM
Feb-04-22 11:25AM
07:00AM
Jan-05-22 01:38PM
Dec-31-21 07:07PM
06:02PM
02:53PM
01:15PM
Dec-30-21 05:57PM
03:31PM
10:00AM
Dec-29-21 11:46PM
05:57PM
04:30PM
10:45AM
Dec-28-21 05:57PM
02:50PM
10:00AM
Dec-27-21 03:16PM
11:00AM
Dec-26-21 08:32AM
Dec-24-21 06:13PM
01:56PM
10:40AM
Dec-23-21 08:38PM
09:30AM
Dec-22-21 06:22PM
05:59PM
04:50PM
02:32PM
11:00AM
10:00AM
Dec-21-21 05:54PM
04:08PM
11:00AM
09:30AM
07:38AM
Dec-20-21 05:47PM
03:49PM
11:00AM
11:00AM
10:00AM
Dec-19-21 09:00PM
08:32AM
Dec-17-21 06:13PM
05:00PM
01:40PM
12:32PM
09:45AM
Dec-16-21 03:50PM
03:00PM
11:00AM
11:00AM
12:49AM
Dec-15-21 05:59PM
04:00PM
01:36PM
12:15PM
09:10AM
Dec-14-21 09:00PM
01:53PM
12:45PM
10:12AM
09:34AM
Dec-13-21 10:00PM
06:57PM
05:15PM
04:30PM
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DGP Co., Ltd.10% OwnerFeb 29 '24Sale1.323,400,0004,488,0000Mar 04 06:36 PM